Trial Profile
A Non-Interventional Long-term Safety Study of Ruxolitinib in Myelofibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2016
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 18 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 11 Sep 2013 New trial record